Navigation Links
China Medical Technologies Reports Third Fiscal Quarter Financial Results
Date:2/18/2011

#12288;

 amortization of

 

 

 

 

 

 

 convertible notesissuance costs

(4,378)

-

(4,378)

(3,941)

-

(3,941)

(597)Interest expense –amortization ofshare lending costs (6)

(2,756)

2,756

-

(2,414)

2,414

-

-Other income (expense), net (7)

225

-

225

22,449

(26,143)

(3,694)

(560)Income (loss) before   income tax

(11,657)

70,363

58,706

60,981

39,860

100,841

15,279Income tax expense

(13,088)

-

(13,088)

(25,199)

-

(25,199)

(3,818)Net income (loss)

(24,745)

70,363

45,618

35,782

39,860

75,642

11,461Earnings (loss) per ADS

 

 

 

 

 

 

 - basic (8)

(0.94)

2.68

1.74

1.37

1.52

2.89

0.44- diluted (8)

(0.94)

2.68

1.74

1.36

1.51

2.87

0.43Weighted average

 

 

 

 

 

 

    number of ADS- basic (8)

26,262,471

-

26,262,471

26,151,808

-

26,151,808

26,151,808- diluted (8)

26,262,471

-

26,262,471

26,377,378

-

26,377,378

26,377,378Notes:

 

For the Three Months EndedDecember 31, 2009December 31, 2010(1) Revenues, net

RMB'000RMB'000US$'000- Molecular diagnostic systems96,166

135,088

20,468- Immunodiagnostic systems

76,154

88,860

13,464172,320

223,948

33,932Molecular diagnostic systems- HPV-DNA chips

-

9
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. China SHESAYS Updates on Progress of Commencing Operations at its New Flagship Hospital
2. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
3. China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011
4. China Medicine Corporation Receives Manufacturing License for rADTZ
5. China SHESAYS Announces Preliminary Unaudited Results for FY 2010; Provides Business Outlook Update for Investors
6. China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011
7. China Sky One Medical Receives Medical Industry Awards
8. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
9. Reportlinker Adds The Top 10 CMOs in China
10. Shareholder Letter from Chairman of China Sky One Medical
11. Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... SPRINGS, Colo. , Aug. 22, 2014 /PRNewswire/ ... specializing in cannabis formulation-based drug development and related ... UFCM iCare,s third international medical cannabis conference taking ... Strasbourg, France , on October 22, ... with other stakeholders, such as researchers, health professionals, ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... -- Phase II,results exceed expectations - Alchemia prepares ... company Alchemia Limited will,commence discussions with the US ... of the Phase II clinical trial,of its metastatic ... from the randomized Phase II clinical trial in ...
... data on Eloxatin(R), Taxotere(R) and on three investigational,agents ... at the 43rd,annual ASCO meeting, BRIDGEWATER, N.J., May ... total of 375 abstracts,indicative of its oncology commitment ... the American Society of Clinical Oncology,(ASCO) in Chicago, ...
Cached Medicine Technology:Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 2Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 3Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:8/23/2014)... (PRWEB) August 23, 2014 Having been in ... dental hygienist from Arlington, Texas, saw a need for an ... toothpaste. "That’s when I came up with the idea for ... provides an effective way for a user to clean the ... to carry multiple items. It also helps avoid plaque buildup ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Hundreds ... filed on behalf of individuals who were allegedly ... replacement line continue to move forward in the ... Liebhard LLP reports. According to an Order dated ... trial program that would allow the litigation’s first ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Youth substance abuse is a serious problem across ... TX. Substance abuse can happen to people of all ... dependency in higher numbers than ever before. Many ... don’t know where to find professional youth rehab. ... because most treatment options are designed for adults. The ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... Md., May 8 Micromet, Inc. (Nasdaq:,MITI), a biopharmaceutical ... the treatment of cancer, inflammation and,autoimmune diseases, today announced ... 2008., Summary of Recent Events:, -- ... phase 1 clinical trial with ...
... Sciences,Inc. (Nasdaq: HGSI ) today announced that John ... of Pfizer Global Research and,Development, has been appointed to ... ), "We are honored to have John ... President and Chief Executive Officer, HGS. "John,s,record of accomplishment ...
... Ortho Organizers, Inc., a,leading manufacturer of orthodontic ... of their new premium O2 Select Orthodontic,Instruments., ... Organizers President and CEO George W. Guttroff ... with the release of O2 Select,Orthodontic Instruments. ...
... than $8 million for medicines and other lifesaving ... ... death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely concerned that the ... increase the death toll among children and other,vulnerable populations, leading to a ...
... Calif., May 8 Samplify Systems, Inc., a,real-time ... Crawford, a leading expert in computed tomography, has ... of experience in the,architecture, design, and development of ... "We are delighted to add Carl,s knowledge of ...
... Hospital buildings can heal,according to the first ... the,physical environment on child patients in health care ... through the,Physical Environment is produced by the National ... partnership with the Center,for Health Design. Findings from ...
Cached Medicine News:Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 9Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 2Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 3Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 4Health News:Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments 2Health News:Myanmar Cyclone a Children's Catastrophe - UNICEF 2Health News:Samplify Systems Adds Computed Tomography Expert Carl Crawford to Technical Team 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: